Adial Pharmaceuticals, Inc. (ADIL)
Automate Your Wheel Strategy on ADIL
With Tiblio's Option Bot, you can configure your own wheel strategy including ADIL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ADIL
- Rev/Share 0.0
- Book/Share 0.1144
- PB 6.0801
- Debt/Equity 0.0
- CurrentRatio 1.9851
- ROIC -4.0941
- MktCap 5495720.0
- FreeCF/Share -0.3702
- PFCF -0.7986
- PE -1.4448
- Debt/Assets 0.0
- DivYield 0
- ROE -2.1888
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
---|---|---|---|---|---|---|---|
No ratings available. |
News
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds
Published: May 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
GLEN ALLEN, Va., May 02, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced its entry into a warrant inducement agreement with an existing healthcare-focused institutional investor of the Company for the immediate exercise of existing Series B Warrants (the "Series B Warrants") to purchase up to 1,418,440 shares of the Company's common stock, par value $0.001 per share (the “Common Stock”), and Series C Warrants (the "Series C Warrants", and together with the Series B …
Read More
Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
New patent covers a treatment method for a broad spectrum of alcohol-related disorders, including additional conditions associated with alcohol use New patent covers a treatment method for a broad spectrum of alcohol-related disorders, including additional conditions associated with alcohol use
Read More
Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
FDA feedback confirms Adial's proposed in vitro bridging strategy to the Phase 3 formulation to fulfill the bridging requirement for the 505(b)(2) regulatory registration pathway for approval
Read More
Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
New Patent covers claims which focus on method for identifying genetic markers in patients with alcohol or opioid related disorders
Read More
About Adial Pharmaceuticals, Inc. (ADIL)
- IPO Date 2018-07-27
- Website https://www.adialpharma.com
- Industry Biotechnology
- CEO Mr. Cary John Claiborne MBA
- Employees 5